Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 30 11:09AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.19 Insider Own15.26% Shs Outstand14.47M Perf Week-0.78%
Market Cap40.08M Forward P/E- EPS next Y-1.15 Insider Trans0.00% Shs Float13.43M Perf Month15.00%
Income-16.05M PEG- EPS next Q-0.17 Inst Own7.88% Short Float4.44% Perf Quarter-11.85%
Sales0.00M P/S- EPS this Y31.74% Inst Trans128.98% Short Ratio7.60 Perf Half Y-29.72%
Book/sh0.38 P/B6.65 EPS next Y-46.50% ROA-194.65% Short Interest0.60M Perf Year-11.85%
Cash/sh0.56 P/C4.49 EPS next 5Y- ROE-283.87% 52W Range1.17 - 8.82 Perf YTD-33.94%
Dividend Est.- P/FCF- EPS past 5Y-17.77% ROI-267.61% 52W High-71.32% Beta-1.70
Dividend TTM- Quick Ratio2.93 Sales past 5Y0.00% Gross Margin- 52W Low116.24% ATR (14)0.18
Dividend Ex-Date- Current Ratio2.93 EPS Y/Y TTM-7.40% Oper. Margin0.00% RSI (14)59.69 Volatility7.44% 8.14%
Employees4 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price11.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-13.47% Payout- Rel Volume0.05 Prev Close2.50
Sales Surprise- EPS Surprise-86.67% Sales Q/Q- EarningsMay 15 BMO Avg Volume78.34K Price2.53
SMA2012.37% SMA5019.74% SMA200-13.33% Trades Volume1,167 Change1.20%
May-16-24 03:00AM
May-15-24 10:40PM
07:00AM Loading…
May-02-24 07:00AM
Apr-25-24 10:12AM
Apr-23-24 10:57AM
Mar-21-24 03:01AM
Mar-19-24 09:32AM
Mar-18-24 10:01PM
Mar-04-24 07:01AM
Feb-27-24 07:01AM
09:30AM Loading…
Feb-23-24 09:30AM
Feb-16-24 09:30AM
Feb-02-24 09:30AM
Feb-01-24 09:33AM
Jan-29-24 07:00AM
Jan-26-24 10:55AM
Jan-23-24 07:01AM
Jan-19-24 09:30AM
Jan-17-24 01:26PM
Jan-05-24 09:30AM
Jan-03-24 08:00AM
Dec-11-23 07:01AM
Dec-08-23 09:46AM
Dec-07-23 09:20AM
09:30AM Loading…
Dec-01-23 09:30AM
Nov-24-23 09:30AM
Nov-17-23 09:30AM
Nov-15-23 02:35PM
Nov-14-23 07:01AM
Nov-09-23 08:52AM
Nov-02-23 07:01AM
Oct-25-23 07:01AM
Oct-20-23 10:43AM
Oct-19-23 07:01AM
Oct-02-23 07:01AM
Sep-12-23 07:01AM
Aug-22-23 07:01AM
Aug-14-23 07:01AM
Jul-24-23 07:01AM
Jul-11-23 07:00AM
Jul-07-23 09:30AM
Jun-30-23 09:35AM
Jun-20-23 07:01AM
Jun-15-23 07:01AM
May-16-23 08:45AM
May-12-23 07:01AM
May-05-23 05:01PM
Apr-22-23 09:42AM
Apr-21-23 09:30AM
Apr-19-23 07:01AM
Apr-13-23 09:30AM
Apr-11-23 07:01AM
Mar-23-23 04:00PM
Mar-18-23 02:03AM
Mar-16-23 07:01AM
Mar-06-23 08:00AM
Feb-14-23 08:01AM
Feb-07-23 08:49AM
Jan-24-23 07:00AM
Jan-19-23 09:00AM
Jan-16-23 08:01AM
Dec-29-22 06:02AM
Dec-28-22 10:39AM
Nov-14-22 07:01AM
Nov-13-22 08:31AM
Nov-04-22 09:30AM
Nov-01-22 08:01AM
Oct-26-22 08:01AM
Oct-17-22 08:00AM
Oct-10-22 09:30AM
Oct-07-22 09:30AM
Sep-26-22 09:30AM
Sep-23-22 10:15AM
Sep-16-22 09:30AM
Aug-15-22 07:01AM
Aug-04-22 08:01AM
Aug-02-22 09:00AM
Jul-25-22 08:30AM
May-11-22 07:01AM
Apr-29-22 08:01AM
Mar-24-22 03:23PM
Mar-17-22 07:01AM
Mar-16-22 08:01AM
Mar-07-22 08:01AM
Feb-07-22 08:01AM
Dec-06-21 08:01AM
Nov-12-21 06:01PM
Nov-08-21 08:01AM
Nov-01-21 08:01AM
Oct-27-21 08:01AM
Oct-04-21 09:00AM
Sep-30-21 08:00AM
Sep-29-21 08:00AM
Sep-27-21 08:00AM
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sailer CarlDirectorJan 19 '24Option Exercise3.5519,73770,066112,552Jan 22 06:15 AM
DELUCCIA ROBERT JDirectorJan 03 '24Option Exercise3.5519,73770,066960,935Jan 04 04:26 PM
LUCI DAVID PPresident and CEOJan 03 '24Option Exercise3.5519,73770,0661,048,197Jan 04 04:24 PM